Package Leaflet:information for the user
Softacort 3.35 mg/ml eye drops, solution in single-dose containers
Sodium hydrocortisone phosphate
Read the entire package leaflet carefully before starting to use this medication,as it contains important information for you.
Contents of the package leaflet:
This medication is an eye drop solution in single-dose containers containing a substance called hydrocortisone. This substance is a corticosteroid that inhibits inflammation symptoms.
It is used to treat mild allergic or inflammatory conditions of the superficial part of your eye or eyes (conjunctiva).
The eye should not be infected (see Do not use Softacort).
Do not use Softacort
Warnings and precautions
Children
There are no safety and efficacy data in children.
Long-term treatment with corticosteroids can produce adrenal suppression.
Increased eye pressure in children occurs more frequently, with greater severity, and with greater rapidity than in adults.
Using Softacort with other medications
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including medications that can be obtained without a prescription.
Some medications may increase the effects of Softacort, and your doctor may want to monitor you closely if you are using these medications (including some medications for HIV: ritonavir, cobicistat).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
It is unknown whether this medication passes into breast milk. Your doctor will decide whether you can use this medication during breastfeeding.
Driving and using machines
You may experience blurred vision immediately after applying Softacort. Do not drive or use machines until this effect has disappeared.
Softacort contains phosphate
This medication contains 0.227 mg of phosphates in each drop.
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is 2 drops in the affected eye(s), 2 to 4 times a day, as prescribed by your doctor. A gradual reduction in dose is recommended to avoid relapse. The duration of treatment may vary from a few days to a maximum of 14 days.
The same dose is used for both adults and elderly patients.
Use in children
The efficacy and safety have not been established in children.
Instructions for use
This medication is intended for administration in the eye.
To use the eye drops, follow these instructions:
If you use any other eye drops, wait at least 5 minutes between each application.
If you use more Softacort than you should
Rinse your eye with sterile water if too much product has been administered in the eye and there is prolonged irritation.
Contact your doctor or pharmacist immediately.
If you forget to use Softacort
Do not apply an additional drop in the eye to make up for the missed dose.
If you stop treatment with Softacort
Do not stop treatment suddenly. Always consult your doctor if you are considering stopping treatment.
If you have any other questions about using this medication, ask your doctor, pharmacist, or nurse.
Like all medications, this medication can cause side effects, although not everyone gets them.
Frequency not known:cannot be estimated from available data
The following side effects have been reported with medications of the same group (corticosteroids) when used to treat eye conditions.
Frequency unknown:cannot be estimated from available data
If you suffer from severe damage to the transparent layer of the front part of your eye (cornea), treatment with phosphates, in very rare cases, can cause cloudy patches on the cornea due to calcium.
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https//: notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the box, pouch, and single-dose container after CAD or EXP. The expiration date is the last day of the month indicated.
Store below 25°C.
After first opening the pouch:use the single-dose container within one month.
Keep the single-dose containers inside the pouch to protect them from light.
Write the date of first opening of the pouch.
After first opening the single-dose container:use immediately and discard the single-dose container after use.
Sterility cannot be maintained after opening a single-dose container, so you must open a new container before each use.
Medications should not be disposed of through wastewater or household waste. Deposit the containers and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medications you no longer need. This will help protect the environment.
Composition ofSoftacort
1 ml of eye drop solution contains 3.35 mg of sodium hydrocortisone phosphate.
Appearance of the product and container contents
This medication is presented as an eye drop solution in single-dose containers.
The solution is practically transparent, colorless to slightly yellow, practically free of particles, presented inside a pouch with 10 units, each single-dose container contains 0.4 ml of eye drop solution.
The boxes contain 10 (1 x 10), 20 (2 x 10), 30 (3 x 10), or 60 (6 x 10) single-dose containers.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
LABORATOIRES THEA
12 RUE LOUIS BLERIOT
63017 CLERMONT-FERRAND CEDEX 2
FRANCE
Manufacturer
LABORATOIRES UNITHER
1 rue de l’Arquerie
50200 Coutances
FRANCE
or
LABORATOIRES THEA
12, rue Louis Blériot
63017 CLERMONT-FERRAND Cedex 2
FRANCE
Local representative
LABORATORIOS THEA, S.A.
C/ Enric Granados nº 86-88, 2ª planta
08008 – BARCELONA
This medication is authorized in the Member States of the European Economic Area under the following names:
Germany, Austria, Bulgaria, Cyprus, Croatia, Denmark, Slovenia, Spain, Finland, France, Greece, Iceland, Norway, Poland, Portugal, Czech Republic, Slovak Republic, United Kingdom, Romania, Sweden Softacort
Belgium, Netherlands, Luxembourg Softacor
Ireland Zoftazot
Italy Sofacor
Date of last revision of this package leaflet: October 2023
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.